PET/CT Radiotracer Shows High Accuracy for Cardiac Amyloidosis Diagnosis

A recent clinical trial published in the Journal of the American Medical Association reported that a novel PET/CT radiotracer exhibits high sensitivity and specificity for diagnosing cardiac amyloidosis, a rare disorder that leads to abnormal protein deposits in the heart and can progress to heart failure. The study evaluated the imaging agent in a cohort of patients with suspected cardiac amyloidosis and found that it accurately distinguished amyloid‑laden myocardium from normal cardiac tissue, outperforming conventional diagnostic methods.

The trial’s findings underscore the potential of PET/CT imaging to provide a non‑invasive, rapid, and reliable diagnostic tool for this increasingly recognized cause of heart failure. By enabling earlier detection, the radiotracer could facilitate timely therapeutic interventions and improve patient outcomes. The research team emphasized that further studies are needed to confirm these results across larger, diverse populations and to integrate the technique into routine clinical practice.